Economic Evaluation of Nivolumab in Gastric and Gastroesophageal Cancer: A Systematic Review

Authors: Jaberi, Nasim; Habibian, Mostafa; Foruzanfar, Faeze; Rezapour, Aziz; Afshari, Somayeh; Arabloo, Jalal

Source journal: Clinical therapeutics (2026-11-17)

DOI: 10.1016/j.clinthera.2026.10.008

Abstract

PURPOSE: Nivolumab, a programmed cell death protein-1 (PD-1) immune checkpoint inhibitor, has demonstrated substantial survival benefits in patients with gastric and gastroesophageal cancers; however, its high acquisition cost raises important concerns regarding economic value and affordability. Although multiple economic evaluations have examined nivolumab-based treatment strategies, the available evidence remains fragmented across therapeutic settings and healthcare systems (HS). This review aimed to synthesize the global cost-effectiveness evidence of nivolumab-based therapies, assess how economic outcomes vary across different treatment strategies, healthcare settings, and modeling approaches, and identify key determinants contributing to variability in cost-effectiveness conclusions. METHODS: A systematic review was conducted according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses 2020 guidelines. PubMed, Embase, Scopus, Web of Science, and additional sources were systematically searched to identify full economic evaluations evaluating nivolumab in gastric and gastroesophageal cancers. Studies were selected based on predefined eligibility criteria, and methodological quality was assessed using the CHEERS 2022 checklist. Because of substantial heterogeneity in study methodology, economic models, and input parameters, quantitative pooling was not feasible; therefore, findings were synthesized qualitatively. All incremental cost-effectiveness ratios were standardized to 2024 US dollars. FINDINGS: Twenty-three studies satisfied the inclusion criteria and demonstrated generally high methodological quality. Most studies were conducted in high-income countries and primarily used Markov, partitioned survival, or decision-analytic models from payer or HS perspectives. Six studies concluded that nivolumab-based strategies were cost-effective within the country-specific willingness-to-pay thresholds, with favorable findings reported predominantly in high-income countries, whereas cost-effectiveness was rarely demonstrated in low- and middle-income settings. Economic outcomes varied substantially according to treatment line, comparator strategy, HS characteristics, and clinical assumptions. The principal determinants influencing cost-effectiveness included hazard ratios, overall survival duration, progression-free survival, utility values, drug acquisition costs, discount rates, body surface area, and patient weight. IMPLICATIONS: Nivolumab-based therapies may offer substantial clinical and economic value; however, their cost-effectiveness remains highly context-dependent and sensitive to local pricing structures, willingness-to-pay thresholds, and model assumptions. Interpretation of current evidence should be undertaken cautiously because available studies are predominantly derived from high-income countries and exhibit substantial methodological heterogeneity, limiting cross-study comparability and generalizability to resource-constrained settings. These findings support value-based oncology decision-making while highlighting the need for context-specific economic evaluations, real-world evidence generation, and innovative pricing strategies to improve equitable access to cancer immunotherapies.

Read the full text

Related topics

Related open access articles

Abstract and bibliographic data from PubMed (U.S. National Library of Medicine). Copyright of the abstract belongs to the original publisher or authors.